Evidence map›Paper›PMID 33990769›Full record

ArticleMolecular psychiatry2021

mTOR kinase activity disrupts a phosphorylation signaling network in schizophrenia brain.

Radhika Chadha, Khaled Alganem, Robert E Mccullumsmith, James H Meador-Woodruff

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Maternal SARS-CoV-2 exposure alters infant DNA methylation.Brain, behavior, & immunity - health · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Molecular Features Triggered by Antipsychotic Medication in Brain Cells.Advances in experimental medicine and biology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Radhika ChadhaDepartment of Neurobiology, University of Utah, Salt Lake City, UT, USA. radhika.chadha@neuro.utah.edu.
Khaled AlganemDepartment of Neurosciences, University of Toledo College of Medicine, Toledo, OH, USA.
Robert E MccullumsmithDepartment of Neurosciences, University of Toledo College of Medicine, Toledo, OH, USA.
James H Meador-WoodruffDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA.
University of Toledo · USUniversity of Alabama at Birmingham · USUniversity of Utah · US

Funding

Translational assessment of brain bioenergetic function in schizophreniaR01MH121102 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI MARANO, CHRISTOPHER, MCCULLUMSMITH, ROBERT E · 2020 to 2024
$3.7M
Cell-specific analysis of sub-kinomes in schizophreniaR01MH107487 · NIMH · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI MCCULLUMSMITH, ROBERT E, MELLER, JAREK · 2016 to 2020
$1.9M
NIMH NIH HHS R01 MH107487
6 · The paper itself

Abstract

The AKT-mTOR signaling transduction pathway plays an important role in neurodevelopment and synaptic plasticity. mTOR is a serine/threonine kinase that modulates signals from multiple neurotransmitters and phosphorylates specific proteins to regulate protein synthesis and cytoskeletal organization. There is substantial evidence demonstrating abnormalities in AKT expression and activity in different schizophrenia (SZ) models. However, direct evidence for dysregulated mTOR kinase activity and its consequences on downstream effector proteins in SZ pathophysiology is lacking. Recently, we reported reduced phosphorylation of mTOR at an activating site and abnormal mTOR complex formation in the SZ dorsolateral prefrontal cortex (DLPFC). Here, we expand on our hypothesis of disrupted mTOR signaling in the SZ brain and studied the expression and activity of downstream effector proteins of mTOR complexes and the kinase activity profiles of SZ subjects. We found that S6RP phosphorylation, downstream of mTOR complex I, is reduced, whereas PKCα phosphorylation, downstream of mTOR complex II, is increased in SZ DLPFC. In rats chronically treated with haloperidol, we showed that S6RP phosphorylation is increased in the rat frontal cortex, suggesting a potential novel mechanism of action for antipsychotics. We also demonstrated key differences in kinase signaling networks between SZ and comparison subjects for both males and females using kinome peptide arrays. We further investigated the role of mTOR kinase activity by inhibiting it with rapamycin in postmortem tissue and compared the impact of mTOR inhibition in SZ and comparison subjects using kinome arrays. We found that SZ subjects are globally more sensitive to rapamycin treatment and AMP-activated protein kinase (AMPK) contributes to this differential kinase activity. Together, our findings provide new insights into the role of mTOR as a master regulator of kinase activity in SZ and suggest potential targets for therapeutic intervention.

Indexed as

SchizophreniaAnimalsBrainFemaleMalePhosphorylationProto-Oncogene Proteins c-aktRatsTOR Serine-Threonine KinasesmTOR protein, ratProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinases

Identifiers

PMID33990769
OpenAlexW3162293854

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.